http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 02 Jul 2026 08:31:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Burning+Rock+Biotech++++++For%3A+Jun+11++Filed+by%3A+Han+Yusheng/26724385.html si-local-file:///var/storage/secattach/20260702/26724385.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Burning+Rock+Biotech++++++For%3A+Jun+11++Filed+by%3A+Han+Yusheng/26724385.html Thu, 02 Jul 2026 08:31:00 -0400 BNR O.48105830 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Burning+Rock+Biotech++++++For%3A+Jun+11++Filed+by%3A+Han+Yusheng/26724385.html si-local-file:///var/storage/secattach/20260702/26724385.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Burning+Rock+Biotech++++++For%3A+Jun+11++Filed+by%3A+Han+Yusheng/26724385.html Thu, 02 Jul 2026 08:31:00 -0400 BNR O.48105830 http://www.streetinsider.com/Insider+Trades/Burning+Rock+founder+buys+%24618K+in+company+ADS+shares/26723982.html <p>Burning Rock Biotech Limited (NASDAQ: BNR) founder, chairman, and chief executive officer Yusheng Han purchased 73,141 of the company's American Depositary Shares (ADSs) for $618,217.72 from the open market, according to a press release statement.</p><p>The transaction brings Han's total ADS purchases across three consecutive post-earnings trading windows to 145,874 shares at an aggregate cost of $1,976,542.90, including 72,733 ADSs acquired during the prior two post-earnings trading windows.</p><p>The company said the purchases were conducted in compliance with applicable rules and regulations and the company's insider trading policy.</p><p>Han may continue to purchase the company's ADSs through open-market transactions, privately negotiated transactions, block http://www.streetinsider.com/Insider+Trades/Burning+Rock+founder+buys+%24618K+in+company+ADS+shares/26723982.html Thu, 02 Jul 2026 07:22:44 -0400 BNR http://www.streetinsider.com/Corporate+News/Burning+Rock+founder+buys+%24618K+in+company+ADS+shares/26723982.html <p>Burning Rock Biotech Limited (NASDAQ: BNR) founder, chairman, and chief executive officer Yusheng Han purchased 73,141 of the company's American Depositary Shares (ADSs) for $618,217.72 from the open market, according to a press release statement.</p><p>The transaction brings Han's total ADS purchases across three consecutive post-earnings trading windows to 145,874 shares at an aggregate cost of $1,976,542.90, including 72,733 ADSs acquired during the prior two post-earnings trading windows.</p><p>The company said the purchases were conducted in compliance with applicable rules and regulations and the company's insider trading policy.</p><p>Han may continue to purchase the company's ADSs through open-market transactions, privately negotiated transactions, block http://www.streetinsider.com/Corporate+News/Burning+Rock+founder+buys+%24618K+in+company+ADS+shares/26723982.html Thu, 02 Jul 2026 07:22:44 -0400 BNR http://www.streetinsider.com/Press+Releases/Burning+Rock+Announces+Founder%E2%80%99s+Purchase+of+Its+ADSs/26723964.html <p align="left">GUANGZHOU, China, July 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its founder, chairman of the board of directors and chief executive officer, Mr. Yusheng Han, has purchased 73,141 of the Company’s ADSs for US$618,217.72 from the open market, which was conducted in compliance with the applicable rules and regulations and the Company’s insider trading policy. As of the date of this press release, combined with 72,733 ADSs http://www.streetinsider.com/Press+Releases/Burning+Rock+Announces+Founder%E2%80%99s+Purchase+of+Its+ADSs/26723964.html Thu, 02 Jul 2026 07:19:00 -0400 BNR BNR O.48105830 http://www.streetinsider.com/Press+Releases/Burning+Rock+Announces+Founder%E2%80%99s+Purchase+of+Its+ADSs/26723964.html <p align="left">GUANGZHOU, China, July 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its founder, chairman of the board of directors and chief executive officer, Mr. Yusheng Han, has purchased 73,141 of the Company’s ADSs for US$618,217.72 from the open market, which was conducted in compliance with the applicable rules and regulations and the Company’s insider trading policy. As of the date of this press release, combined with 72,733 ADSs http://www.streetinsider.com/Press+Releases/Burning+Rock+Announces+Founder%E2%80%99s+Purchase+of+Its+ADSs/26723964.html Thu, 02 Jul 2026 07:19:00 -0400 BNR BNR O.48105830 http://www.streetinsider.com/Press+Releases/Burning+Rock+Announces+Founder%E2%80%99s+Purchase+of+Its+ADSs/26723964.html <p align="left">GUANGZHOU, China, July 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its founder, chairman of the board of directors and chief executive officer, Mr. Yusheng Han, has purchased 73,141 of the Company’s ADSs for US$618,217.72 from the open market, which was conducted in compliance with the applicable rules and regulations and the Company’s insider trading policy. As of the date of this press release, combined with 72,733 ADSs http://www.streetinsider.com/Press+Releases/Burning+Rock+Announces+Founder%E2%80%99s+Purchase+of+Its+ADSs/26723964.html Thu, 02 Jul 2026 07:19:00 -0400 BNR BNR O.48105830 http://www.streetinsider.com/Globe+Newswire/Burning+Rock+Announces+Founder%E2%80%99s+Purchase+of+Its+ADSs/26723964.html <p align="left">GUANGZHOU, China, July 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its founder, chairman of the board of directors and chief executive officer, Mr. Yusheng Han, has purchased 73,141 of the Company’s ADSs for US$618,217.72 from the open market, which was conducted in compliance with the applicable rules and regulations and the Company’s insider trading policy. As of the date of this press release, combined with 72,733 ADSs http://www.streetinsider.com/Globe+Newswire/Burning+Rock+Announces+Founder%E2%80%99s+Purchase+of+Its+ADSs/26723964.html Thu, 02 Jul 2026 07:19:00 -0400 BNR BNR O.48105830 http://www.streetinsider.com/Globe+Newswire/Burning+Rock+Announces+Founder%E2%80%99s+Purchase+of+Its+ADSs/26723964.html <p align="left">GUANGZHOU, China, July 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its founder, chairman of the board of directors and chief executive officer, Mr. Yusheng Han, has purchased 73,141 of the Company’s ADSs for US$618,217.72 from the open market, which was conducted in compliance with the applicable rules and regulations and the Company’s insider trading policy. As of the date of this press release, combined with 72,733 ADSs http://www.streetinsider.com/Globe+Newswire/Burning+Rock+Announces+Founder%E2%80%99s+Purchase+of+Its+ADSs/26723964.html Thu, 02 Jul 2026 07:19:00 -0400 BNR BNR O.48105830 http://www.streetinsider.com/Globe+Newswire/Burning+Rock+Announces+Founder%E2%80%99s+Purchase+of+Its+ADSs/26723964.html <p align="left">GUANGZHOU, China, July 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its founder, chairman of the board of directors and chief executive officer, Mr. Yusheng Han, has purchased 73,141 of the Company’s ADSs for US$618,217.72 from the open market, which was conducted in compliance with the applicable rules and regulations and the Company’s insider trading policy. As of the date of this press release, combined with 72,733 ADSs http://www.streetinsider.com/Globe+Newswire/Burning+Rock+Announces+Founder%E2%80%99s+Purchase+of+Its+ADSs/26723964.html Thu, 02 Jul 2026 07:19:00 -0400 BNR BNR O.48105830 http://www.streetinsider.com/Press+Releases/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html <p align="left">GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2026.</p> <p><strong>Recent Business</strong> <strong>Updates</strong></p> <ul type="disc"><li style="margin-top:6.7pt;"><strong>Early </strong><strong>Detection, Therapy Selection &amp; MRD</strong> <ul type="disc"><li style="margin-top:6.75pt;">Presented multiple study results at the 2026 AACR in April, showcasing validation data on MMcall, CanCatch Surf, 25-plex ddPCR, and SPIRAL.</li><li style="margin-top:6.75pt;">Presented study results at <em>Journal for ImmunoTherapy of Cancer </em>in April 2026. “A http://www.streetinsider.com/Press+Releases/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html Tue, 09 Jun 2026 06:38:00 -0400 A.50216929 BNR BNR O.34714696 O.48105830 http://www.streetinsider.com/Press+Releases/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html <p align="left">GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2026.</p> <p><strong>Recent Business</strong> <strong>Updates</strong></p> <ul type="disc"><li style="margin-top:6.7pt;"><strong>Early </strong><strong>Detection, Therapy Selection &amp; MRD</strong> <ul type="disc"><li style="margin-top:6.75pt;">Presented multiple study results at the 2026 AACR in April, showcasing validation data on MMcall, CanCatch Surf, 25-plex ddPCR, and SPIRAL.</li><li style="margin-top:6.75pt;">Presented study results at <em>Journal for ImmunoTherapy of Cancer </em>in April 2026. “A http://www.streetinsider.com/Press+Releases/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html Tue, 09 Jun 2026 06:38:00 -0400 A.50216929 BNR BNR O.34714696 O.48105830 http://www.streetinsider.com/Press+Releases/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html <p align="left">GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2026.</p> <p><strong>Recent Business</strong> <strong>Updates</strong></p> <ul type="disc"><li style="margin-top:6.7pt;"><strong>Early </strong><strong>Detection, Therapy Selection &amp; MRD</strong> <ul type="disc"><li style="margin-top:6.75pt;">Presented multiple study results at the 2026 AACR in April, showcasing validation data on MMcall, CanCatch Surf, 25-plex ddPCR, and SPIRAL.</li><li style="margin-top:6.75pt;">Presented study results at <em>Journal for ImmunoTherapy of Cancer </em>in April 2026. “A http://www.streetinsider.com/Press+Releases/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html Tue, 09 Jun 2026 06:38:00 -0400 A.50216929 BNR BNR O.34714696 O.48105830 http://www.streetinsider.com/Press+Releases/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html <p align="left">GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2026.</p> <p><strong>Recent Business</strong> <strong>Updates</strong></p> <ul type="disc"><li style="margin-top:6.7pt;"><strong>Early </strong><strong>Detection, Therapy Selection &amp; MRD</strong> <ul type="disc"><li style="margin-top:6.75pt;">Presented multiple study results at the 2026 AACR in April, showcasing validation data on MMcall, CanCatch Surf, 25-plex ddPCR, and SPIRAL.</li><li style="margin-top:6.75pt;">Presented study results at <em>Journal for ImmunoTherapy of Cancer </em>in April 2026. “A http://www.streetinsider.com/Press+Releases/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html Tue, 09 Jun 2026 06:38:00 -0400 A.50216929 BNR BNR O.34714696 O.48105830 http://www.streetinsider.com/Press+Releases/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html <p align="left">GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2026.</p> <p><strong>Recent Business</strong> <strong>Updates</strong></p> <ul type="disc"><li style="margin-top:6.7pt;"><strong>Early </strong><strong>Detection, Therapy Selection &amp; MRD</strong> <ul type="disc"><li style="margin-top:6.75pt;">Presented multiple study results at the 2026 AACR in April, showcasing validation data on MMcall, CanCatch Surf, 25-plex ddPCR, and SPIRAL.</li><li style="margin-top:6.75pt;">Presented study results at <em>Journal for ImmunoTherapy of Cancer </em>in April 2026. “A http://www.streetinsider.com/Press+Releases/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html Tue, 09 Jun 2026 06:38:00 -0400 A.50216929 BNR BNR O.34714696 O.48105830 http://www.streetinsider.com/Globe+Newswire/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html <p align="left">GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2026.</p> <p><strong>Recent Business</strong> <strong>Updates</strong></p> <ul type="disc"><li style="margin-top:6.7pt;"><strong>Early </strong><strong>Detection, Therapy Selection &amp; MRD</strong> <ul type="disc"><li style="margin-top:6.75pt;">Presented multiple study results at the 2026 AACR in April, showcasing validation data on MMcall, CanCatch Surf, 25-plex ddPCR, and SPIRAL.</li><li style="margin-top:6.75pt;">Presented study results at <em>Journal for ImmunoTherapy of Cancer </em>in April 2026. “A http://www.streetinsider.com/Globe+Newswire/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html Tue, 09 Jun 2026 06:38:00 -0400 A.50216929 BNR BNR O.34714696 O.48105830 http://www.streetinsider.com/Globe+Newswire/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html <p align="left">GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2026.</p> <p><strong>Recent Business</strong> <strong>Updates</strong></p> <ul type="disc"><li style="margin-top:6.7pt;"><strong>Early </strong><strong>Detection, Therapy Selection &amp; MRD</strong> <ul type="disc"><li style="margin-top:6.75pt;">Presented multiple study results at the 2026 AACR in April, showcasing validation data on MMcall, CanCatch Surf, 25-plex ddPCR, and SPIRAL.</li><li style="margin-top:6.75pt;">Presented study results at <em>Journal for ImmunoTherapy of Cancer </em>in April 2026. “A http://www.streetinsider.com/Globe+Newswire/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html Tue, 09 Jun 2026 06:38:00 -0400 A.50216929 BNR BNR O.34714696 O.48105830 http://www.streetinsider.com/Globe+Newswire/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html <p align="left">GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2026.</p> <p><strong>Recent Business</strong> <strong>Updates</strong></p> <ul type="disc"><li style="margin-top:6.7pt;"><strong>Early </strong><strong>Detection, Therapy Selection &amp; MRD</strong> <ul type="disc"><li style="margin-top:6.75pt;">Presented multiple study results at the 2026 AACR in April, showcasing validation data on MMcall, CanCatch Surf, 25-plex ddPCR, and SPIRAL.</li><li style="margin-top:6.75pt;">Presented study results at <em>Journal for ImmunoTherapy of Cancer </em>in April 2026. “A http://www.streetinsider.com/Globe+Newswire/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html Tue, 09 Jun 2026 06:38:00 -0400 A.50216929 BNR BNR O.34714696 O.48105830 http://www.streetinsider.com/Globe+Newswire/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html <p align="left">GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2026.</p> <p><strong>Recent Business</strong> <strong>Updates</strong></p> <ul type="disc"><li style="margin-top:6.7pt;"><strong>Early </strong><strong>Detection, Therapy Selection &amp; MRD</strong> <ul type="disc"><li style="margin-top:6.75pt;">Presented multiple study results at the 2026 AACR in April, showcasing validation data on MMcall, CanCatch Surf, 25-plex ddPCR, and SPIRAL.</li><li style="margin-top:6.75pt;">Presented study results at <em>Journal for ImmunoTherapy of Cancer </em>in April 2026. “A http://www.streetinsider.com/Globe+Newswire/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html Tue, 09 Jun 2026 06:38:00 -0400 A.50216929 BNR BNR O.34714696 O.48105830 http://www.streetinsider.com/Globe+Newswire/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html <p align="left">GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2026.</p> <p><strong>Recent Business</strong> <strong>Updates</strong></p> <ul type="disc"><li style="margin-top:6.7pt;"><strong>Early </strong><strong>Detection, Therapy Selection &amp; MRD</strong> <ul type="disc"><li style="margin-top:6.75pt;">Presented multiple study results at the 2026 AACR in April, showcasing validation data on MMcall, CanCatch Surf, 25-plex ddPCR, and SPIRAL.</li><li style="margin-top:6.75pt;">Presented study results at <em>Journal for ImmunoTherapy of Cancer </em>in April 2026. “A http://www.streetinsider.com/Globe+Newswire/Burning+Rock+Reports+First+Quarter+2026+Financial+Results/26619919.html Tue, 09 Jun 2026 06:38:00 -0400 A.50216929 BNR BNR O.34714696 O.48105830 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Burning+Rock+Biotech++++++For%3A+Jun+09/26619788.html si-local-file:///var/storage/secattach/20260609/26619788.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Burning+Rock+Biotech++++++For%3A+Jun+09/26619788.html Tue, 09 Jun 2026 06:05:00 -0400 BNR O.48105830 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Burning+Rock+Biotech++++++For%3A+Jun+09/26619788.html si-local-file:///var/storage/secattach/20260609/26619788.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Burning+Rock+Biotech++++++For%3A+Jun+09/26619788.html Tue, 09 Jun 2026 06:05:00 -0400 BNR O.48105830 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Burning+Rock+Biotech+++++++++++++++++++Filed+by%3A+Kynam+Capital+Management%2C+LP/26504690.html si-local-file:///var/storage/secattach/20260515/26504690.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Burning+Rock+Biotech+++++++++++++++++++Filed+by%3A+Kynam+Capital+Management%2C+LP/26504690.html Fri, 15 May 2026 16:02:00 -0400 BNR O.48105830 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Burning+Rock+Biotech+++++++++++++++++++Filed+by%3A+Kynam+Capital+Management%2C+LP/26504690.html si-local-file:///var/storage/secattach/20260515/26504690.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Burning+Rock+Biotech+++++++++++++++++++Filed+by%3A+Kynam+Capital+Management%2C+LP/26504690.html Fri, 15 May 2026 16:02:00 -0400 BNR O.48105830 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Burning+Rock+Biotech+++++++++++++++++++Filed+by%3A+CRCM+LP/26487465.html si-local-file:///var/storage/secattach/20260513/26487465.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Burning+Rock+Biotech+++++++++++++++++++Filed+by%3A+CRCM+LP/26487465.html Wed, 13 May 2026 17:12:00 -0400 BNR O.48105830